Immuneering Corporation — Company profile
Healthcare · Biotechnology · United States
Last price 4.02 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 260.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Details
| Name | Immuneering Corporation |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 65 |
| Founded | 2008 |
| Ipo Date | 2021-07-30 |
| Ceo | Benjamin Zeskind |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 15.00 |
| Isin | US45254E1073 |
| Cusip | 45254E107 |
| Cik | 1790340 |
| Sic | 2834 |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Robert J. Carpenter M.B.A., M.S. | Co-Founder and Chair Emeritus |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Michael D. Bookman J.D. | Chief Legal Officer and Secretary |
| Andrew W. Gengos | Chief Financial Officer and Treasurer |
| Paula George CPA | Senior Director of Accounting and Operations and Assistant Corporate Controller |
| Mallory Morales CPA | Senior Vice President of Finance, Chief Accounting Officer and Assistant Treasurer |
| Jyoti Joshi | Director of Quality Systems and Compliance |
| David Caouette | Vice President of Corporate Communications |
| Leah R. Neufeld | Chief People Officer |
Contact
| Address | 245 Main Street, Second Floor, Cambridge, Massachusetts 02142, United States |
| Phone | 617 500 8080 |
| Website | https://immuneering.com |